{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036135","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.452521+00:00","generated_at":"2026-06-04T07:35:47.468741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gyre Therapeutics reports 2023 revenue $113.5M, net loss $85.5M; ETUARY sales up 13%","bullets":["Full year 2023 revenue of $113.5M, up from $102.3M in 2022; net loss of $85.5M vs net income of $4.3M in 2022.","ETUARY sales reached $112.1M in 2023, a 13% increase; sales team covers 35,512 hospitals across PRC.","Cash and cash equivalents $33.5M as of Dec 31, 2023 vs $25.2M end of 2022.","Phase 3 trial for F351 in CHB-associated liver fibrosis topline data expected by early 2025; U.S. Phase 2a in NASH planned for 2025.","Appointed Han Ying as CEO in January 2024; completed business combination with GNI in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036135","json":"https://secwatch.observer/filing/0000950170-24-036135.json","markdown":"https://secwatch.observer/filing/0000950170-24-036135.md","text":"https://secwatch.observer/filing/0000950170-24-036135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/gyre-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:35:47.468741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f79f042a975161bb4fa6ee530c6f3b7fdb504ba","claim":"GYRE THERAPEUTICS, INC. reported year ended December 31, 2023 results: revenue $112.1 million.","evidence_excerpt":"inflammation modulators. ETUARY became commercially available in the PRC in 2011 and has been included in the National Reimbursement Drug List since 2017. • Generated sales of $112.1 million in 2023. For the year ended December 31, 2023, Gyre Pharmaceuticals generated $112.1 million in sales of ETUARY, representing an increase of 13% from the previous year. As of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$112.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}